Genmab — Januar 2018
-
Is it pure coïncidence that this company (in Utrecht, just next to Genmab) announces first dosing of bispecific antibody targeting HER2 and HER3 receptors today?? Merus Announces First Patient Dosed in a Phase 2 Clinical Trial of MCLA-128 in Two Metastatic Breast Cancer Patient Populations
https://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=262078 -
A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens https://clinicaltrials.gov/ct2/show/NCT03412565?term=daratumumab+OR+ofatumumab&lupd_s=01%2F25%2F2018&rank=4
-
Det går squ´meget godt nu
-
Som sagt før " Genmab er som en rutschebane i Fårup...det går SÅ hurtigt ned og OP
-
Vi kan vist stadig være enig om at shorterne i aktien er meget venlige og humane. Vi ser absolut ingen aggressivitet og forsøg på at trykke kursen ned under støttepunkter og udløse stop loses over en bred kam.
-
Enig med Pensionisten. Der er udmattelse at spore. Det har vi dog prøvet før gennem årene.
-
Jeg formoder, at vi kursmæssigt danner base for øjeblikket. Nyorienteringen starter så efter næste Q&A d. 22. februar.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind